medigraphic.com
Colegio de Medicina Interna de México.

2014, Number 5

<< Back Next >>

Med Int Mex 2014; 30 (5)

Capillary glycosylated hemoglobin measurement as screening in diabetes mellitus type 2

Vargas-Contreras EA, Gómez-Moreno JH, Conde-Mercado JM

Language: Spanish
References: 25
Page: 538-545
PDF size: 482.32 Kb.


ABSTRACT

Background: In 2010 American Diabetes Association (ADA) and the Expert Committee on Diabetes included glycated hemoglobin diagnostic test as an additional measurement. Its use widespread from monitoring to diagnostic and screening, stating as a diagnostic alternative, without replacing plasma glycose.
Objective: To determine the sensitivity of glycated hemoglobin measurement through a capillary device in screening of diabetes mellitus type 2.
Material and method: A prospective, descriptive and observational study included 20-30-year-old patients, with a Findrisk questionnaire score of 12-14 points, who were submitted to capillary and venous glycosylated hemoglobin determination.
Results: Twenty subjects were included, 7 men (35%) and 13 women (65%), measurement of capillary glycosylated hemoglobin had an average of 5.2 ± 0.1654%, consistent with venous specific determination of 25%. Confidence interval at 95% (95% CI) between -0210 to 0130, χ2 0.628, p ‹0.492.
Conclusions: Capillary measuring of glycated hemoglobin had a higher specificity and equal sensitivity than those of venous determination; thus, it is an option for the diagnosis and monitoring of patients at low cost, affordable, quick and comfortable. The combination of HbA1c and Findrisk test optimizes the early diagnosis of disease states.


REFERENCES

  1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2014;37:S14-S80.

  2. Asociación Latinoamericana de Diabetes. Guías ALAD sobre el Diagnóstico, Control y Tratamiento de la Diabetes Mellitus Tipo 2 con Medicina Basada en Evidencia. Revista de la ALAD 2013;1-142.

  3. Organización Mundial de la Salud (OMS). Diabetes. Nota descriptiva núm. 312, Septiembre 2012.

  4. Longo DL, Kasper DL, Jameson JL, Fauci AS, et al. Harrison: Principios de Medicina Interna. 18ª ed. México: McGraw- Hill, 2012;2968-2970.

  5. Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37:S81-S90.

  6. Hernández M, Gutiérrez JP. Diabetes mellitus: la urgencia de reforzar la respuesta en políticas públicas para su prevención y control. Instituto de Nacional Salud Pública. Encuesta Nacional de Salud y Nutrición (ENSANUT) 2012.

  7. Álvarez SE, González CT, Cabrera RE, Conesa GA y col. Algunos aspectos de actualidad sobre la hemoglobina glucosilada y sus aplicaciones. Revista Cubana de Endocrinología 2009;20:141-151.

  8. Pérez PI, Rodríguez WFL, Díaz GEJ, Cabrera JR. Mitos y realidad de la hemoglobina glucosilada. Med Int Méx 2009;25:202-209.

  9. Braga F, Dolci A, Mosca A, Panteghini M. Biological variability of glycated hemoglobin. Clinica Chimica Acta 2010;411:1606-1610.

  10. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010;33:S11-S61.

  11. Diabetes Control and Complications Trial (DCCT): Results of Feasibility Study. Diabetes Care 1987;10:1-19.

  12. UK Prospective Diabetes Study Group: Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

  13. YehudaHandelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. Endocr Pract 2011;17:1-53.

  14. Zamudio VJ. Diagnóstico de diabetes con hemoglobina glicosilada. Rev Eviden Invest Clin 2010;3:58-60.

  15. Sacks DB, Arnold M, Bakris GL, Bruns DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011;34:e61-e99.

  16. Nordin G, Dybkaer R. Recommendation for term and measurement unit for “HbA1c”. Clin Chem Lab Med 2007;45:1081-1082.

  17. Bonora E, Tuomilehto J. The pros and cons of diagnosing diabetes with A1C. Diabetes Care 2011;34:S184-S190.

  18. Braga F, Dolci A, Montagnana M, Pagani F, et al. Revaluation of biological variation of glycated hemoglobin (HbA1c) using an accurately designed protocol and an assay traceable to the IFCC reference system. Clin Chim Acta 2011;412:1412-1416.

  19. Programme for the Prevention of Type 2 Diabetes in Finland 2003-2010. Finnish Diabetes Association.

  20. Mattewal A, Aldasouqi S, Solomon D, Gossain V, Koller A. A1cNow® InView™: A new simple method for office-based glycohemoglobin measurement. J Diabetes Sci Technol 2007;1:880-884.

  21. Carter AW. An analysis of the assessment of glycated hemoglobin using A1cNow+™ point-of-care device compared to central laboratory testing—an important addition to pharmacist-managed diabetes. J Diabetes Sci Technol 2008;2:828-830.

  22. Bode BW, Irvin BE, Pierce JA, Allen M, Clark A. Advances in hemoglobin A1c point of caretechnology. J Diabetes Sci Technol 2007;1:405-411.

  23. Christensen DL, Witte DR, Kaduka L, Jorgensen ME, et al. Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups. Diabetes Care 2010;33:580-582.

  24. Martin E, Ruf E, Landgraf R, Hauner H, et al. FINDRISK questionnaire combined with HbA1c testing as a potential screening strategy for undiagnosed diabetes in a healthy population. Horm Metab Res 2011;43:782-787.

  25. Kumar PR, Bhansali A, Ravikiran M, Bhansali S, et al. Utility of glycated hemoglobin in diagnosing type 2 diabetes mellitus: a community-based study. J Clin Endocrinol Metab 2010;95:1-4.




2020     |     www.medigraphic.com